Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1984 January; 77(1): 45–49.
PMCID: PMC1439574

Optimal chemotherapy for ovarian carcinoma: discussion paper.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (752K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Alberts DS, Samon SE, Chen HS, Surwit EA, Soehnlen B, Young L, Moon TE. In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet. 1980 Aug 16;2(8190):340–342. [PubMed]
  • Blythe JG, Wahl TP. Debulking surgery: does it increase the quality of survival? Gynecol Oncol. 1982 Dec;14(3):396–408. [PubMed]
  • Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon JF. The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentations. Cancer Treat Rep. 1979 Feb;63(2):249–254. [PubMed]
  • Epenetos AA, Britton KE, Mather S, Shepherd J, Granowska M, Taylor-Papadimitriou J, Nimmon CC, Durbin H, Hawkins LR, Malpas JS, et al. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet. 1982 Nov 6;2(8306):999–1005. [PubMed]
  • Fuks Z, Rizel S, Anteby SO, Biran S. Current concepts in cancer: ovary--treatment for stages III and IV. The multimodal approach to the treatment of stage III ovarian carcinoma. Int J Radiat Oncol Biol Phys. 1982 May;8(5):903–908. [PubMed]
  • Greene MH, Boice JD, Jr, Greer BE, Blessing JA, Dembo AJ. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med. 1982 Dec 2;307(23):1416–1421. [PubMed]
  • Hähnel R, Kelsall GR, Martin JD, Masters AM, McCartney AJ, Twaddle E. Estrogen and progesterone receptors in tumors of the human ovary. Gynecol Oncol. 1982 Apr;13(2):145–151. [PubMed]
  • Hunter RE, Reich SD, Griffin TW, Bogden AE. Responsiveness of gynecologic tumors to chemotherapeutic agents in the 6-day subrenal capsule assay. Gynecol Oncol. 1982 Dec;14(3):298–306. [PubMed]
  • Katz ME, Schwartz PE, Kapp DS, Luikart S. Epithelial carcinoma of the ovary: current strategies. Ann Intern Med. 1981 Jul;95(1):98–111. [PubMed]
  • Malkasian GD, Jr, Decker DG, Jorgensen EO, Edmonson JH. Medroxyprogesterone acetate for the treatment of metastatic and recurrent ovarian carcinoma. Cancer Treat Rep. 1977 Aug;61(5):913–914. [PubMed]
  • Selby P, Buick RN, Tannock I. A critical appraisal of the "human tumor stem-cell assay". N Engl J Med. 1983 Jan 20;308(3):129–134. [PubMed]
  • Smith JP, Day TG., Jr Rewiew of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol. 1979 Dec 1;135(7):984–993. [PubMed]
  • Vogl SE, Berenzweig M, Kaplan BH, Moukhtar M, Bulkin W. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979 Feb;63(2):311–317. [PubMed]
  • Ward HW. Progestogen therapy for ovarian carcinoma. J Obstet Gynaecol Br Commonw. 1972 Jun;79(6):555–559. [PubMed]
  • Wiltshaw E, Kroner T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 1976 Jan;60(1):55–60. [PubMed]
  • Young RC. Chemotherapy of ovarian cancer: past and present. Semin Oncol. 1975 Sep;2(3):267–276. [PubMed]
  • Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT., Jr Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261–1266. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press